ABSTRACT
INTRODUCTION
Lb is the most frequent vector-borne illness in the temperate zone of the northern hemisphere. Early publications suggested that like syphilis, maternal Borrelia burgdorferi s.l. infection may seriously influence the outcome of pregnancy. Stillbirth and congenital heart abnormalities have been described. With the exception of some publications, most early case reports have described patients with adverse outcomes following their pregnancies. Incidence and cross sectional studies on populations of one to five thousand pregnant women and/or their offspring hardly found a case of Lb and, therefore, remained inconclusive with respect to risk for adverse pregnancy outcomes. Epidemiological evaluation of treated and untreated patients is also complicated by the low rate of untreated cases present and identified in most populations. Almost every patient in the largest study until the present report on gestational Lb was treated with ceftriaxone. Many years ago, analysis of our recorded data suggested that untreated Lb patients had a much greater chance of suffering an adverse outcome in pregnancy, but the number of the patients was too low to achieve meaningful results. The Center for Tick-borne Diseases, Budapest was opened in 1986 under the leadership of one of the authors (AL). Since then, almost 9000 erythema migrans (EM) patients were seen, including 124 cases in which Borrelia burgdorferi s.l. infection was clinically evident during pregnancy. Here we report our experience with these cases.
RESULTS
Almost every mothers showed the typical sign of Lb, i.e. erythema migrans. Three had acrodermatitis chronica atrophicans and four had facial palsy with intrathecal antibody production (3). We registered 31 adverse outcomes in 24 (19.3%) of the 124 offspring; these are listed in Table 1 . Treatment was administered parenterally to 87 (70%) women and orally to 25 (20.0%). Infection remained untreated in 12 (10%) pregnancies. Adverse outcomes were seen in 7/87 (8%), 9/25 (36%), 8/12 (67%), of the parenterally, orally treated and untreated women, respectively. In comparison to patients treated with antibiotics, untreated women had a significantly higher risk of adverse pregnancy outcomes. Mothers treated orally comparing to iv. treatment had an increased chance to have an adverse outcome. In the adverse pregnancy outcome, the most impressive difference was between the untreated and parenterally treated women (Figure 1 ) The probability of adverse outcome increased by the exposition time (from the first maternal symptom to the treatment or delivery). When the exposition time has reached four months, the probability of adverse outcome increased by 33% (Figure 2 ). There was a higher risk of pregnancy loss if the infection was shortly before or after the conception, while other complication were more frequent when the infection happened during later in the pregnancy (Figure 3) . We had no chance to examine the bacterial invasion of the foetus. 
CONCLUSION
Our findings demonstrate a statistically significant association between untreated Lyme borreliosis and adverse outcome of pregnancy. Many controversial papers have been published and we think that our study is the first in which sufficiently heterogeneous and large numbers of mothers were gathered for statistical evaluation. It seems that a specific syndrome representing a 'congenital Lyme borreliosis' is unlikely. However, spontaneous abortion, stillbirth and preterm birth are frequently published in other studies and also in our series. Pregnancy loss was significantly more frequent amongst untreated patients than among the parenterally treated women in our study population. During the last 18 years, intravenous ceftriaxone was preferred to treatment with oral amoxicillin in our practice. During pregnancy, amoxicillin has lower plasma concentrations and more rapid elimination than in the postpartum or non-pregnant situation. The pharmacokinetics of ceftriaxone, however, is not significantly influenced by pregnancy. In addition, ceftriaxone in vitro is more effective against Borrelia than other beta-lactams. Our present data are definitively support the superiority of high dose iv. penicillin or parenterally administered ceftriaxone over the oral antibiotic treatment. We had no chance to examine the placenta or fetus for direct borrelia invasion in the cases of pregnancy loss, therefore the causal relation remains opened in spite of the statistical association. 
Risk of adverse pregnancy outcome in various comparisons of treatment groups
The red boxes represent the odds ratio (OR), the horizontal grey line are the 95% confidence intervals of estimation. The vertical grey line means the OR=1, ie. there is no difference in the odds of the compared groups. If the confidence interval contains the value OR=1, then the estimation is not significant on the certain level (p<0.05). The size of the red boxes is proportional to the precision of estimation. The differences (Pearson's residuals) between the observed and expected frequencies of contingency table are presented with rectangles. Height and width of the bars are proportional to Pearson's residuals, and the expected counts, respectively. If the observed frequency of a cell is greater than the expected one, the box rises above the baseline, and falls below otherwise.
